Piramal Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	91,338	91,512	81,712	70,816	65,591	58,291
Other Revenue	-	-	-	-	1,750	576.37
Revenue	91,338	91,512	81,712	70,816	67,341	58,868
Revenue Growth (YoY)	9.08%	11.99%	15.39%	5.16%	14.39%	-
Cost of Revenue	35,748	35,551	32,617	29,713	24,512	20,736
Gross Profit	55,590	55,961	49,095	41,103	42,829	38,132
Selling, General & Admin	25,560	25,171	22,034	21,046	15,888	14,761
Other Operating Expenses	16,517	16,299	15,054	13,736	15,477	9,508
Operating Expenses	50,367	49,633	44,493	41,549	37,227	29,301
Operating Income	5,223	6,328	4,601	-446.5	5,602	8,831
Interest Expense	-3,971	-4,179	-4,470	-3,377	-1,888	-1,459
Interest & Investment Income	105.8	105.8	119.2	16.4	6.8	37.11
Earnings From Equity Investments	691	729.3	594.9	543.3	590.3	436.06
Currency Exchange Gain (Loss)	380.9	380.9	304	1,108	168.6	565.57
Other Non Operating Income (Expenses)	883.1	494.5	762.6	523.3	-94.7	-50.12
EBT Excluding Unusual Items	3,312	3,859	1,912	-1,633	4,385	8,361
Merger & Restructuring Charges	-	-	-	-69.6	-150.8	-416.77
Gain (Loss) on Sale of Investments	90.5	90.5	43.5	15.8	19.5	-
Gain (Loss) on Sale of Assets	14.4	14.4	-4.6	-4.8	-5.4	10.52
Asset Writedown	-	-	-	-	-	-377.08
Other Unusual Items	390	182.6	-158.4	490	601.3	1,183
Pretax Income	3,807	4,146	1,793	-1,202	4,850	8,760
Income Tax Expense	2,826	3,235	1,615	663.1	1,090	1,052
Net Income	980.7	911.3	178.2	-1,865	3,760	7,708
Net Income to Common	980.7	911.3	178.2	-1,865	3,760	7,708
Net Income Growth	253.28%	411.39%	-	-	-51.23%	-
Shares Outstanding (Basic)	1,322	1,323	1,281	1,190	1,179	628
Shares Outstanding (Diluted)	1,329	1,331	1,284	1,190	1,179	628
Shares Change (YoY)	1.48%	3.67%	7.85%	0.95%	87.83%	-
EPS (Basic)	0.74	0.69	0.14	-1.57	3.19	12.28
EPS (Diluted)	0.73	0.68	0.14	-1.57	3.19	12.28
EPS Growth	245.21%	388.86%	-	-	-74.02%	-
Free Cash Flow	-	2,279	2,925	-4,809	-1,231	-42.55
Free Cash Flow Per Share	-	1.71	2.28	-4.04	-1.04	-0.07
Dividend Per Share	-	0.140	0.110	-	0.980	-
Dividend Growth	-	27.27%	-	-	-	-
Gross Margin	60.86%	61.15%	60.08%	58.04%	63.60%	64.78%
Operating Margin	5.72%	6.92%	5.63%	-0.63%	8.32%	15.00%
Profit Margin	1.07%	1.00%	0.22%	-2.63%	5.58%	13.09%
Free Cash Flow Margin	-	2.49%	3.58%	-6.79%	-1.83%	-0.07%
EBITDA	12,759	13,715	11,391	5,764	11,099	12,970
EBITDA Margin	13.97%	14.99%	13.94%	8.14%	16.48%	22.03%
D&A For EBITDA	7,537	7,387	6,790	6,211	5,497	4,139
EBIT	5,223	6,328	4,601	-446.5	5,602	8,831
EBIT Margin	5.72%	6.92%	5.63%	-0.63%	8.32%	15.00%
Effective Tax Rate	74.24%	78.02%	90.06%	-	22.48%	12.01%
Revenue as Reported	93,074	92,860	83,466	73,067	68,349	59,806
Advertising Expenses	-	1,767	1,423	1,762	1,513	-

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.